Zoetis Launches Portela® in Canada and Europe, Introducing the First Long-Acting Anti-NGF Therapy for Feline Osteoarthritis Pain Zoetis Inc. has announced the commercial launch of Portela® (relfovetmab) across Canada and the member states of the European Union, marking an important…
Teleflex Awarded National Group Purchasing Agreement with Premier to Expand Access to Advanced Vascular Access Solutions Teleflex Incorporated, a global provider of medical technologies designed to improve patient care and clinical outcomes, has announced that it has been awarded a…
LAPIX Therapeutics Completes Enrollment in Rheumatoid Arthritis Cohort of LPX-TI641 Clinical Trial, Advancing Development of First-in-Class Oral TIM 3/4 Agonist LAPIX Therapeutics, a clinical-stage biotechnology company focused on developing innovative immunomodulatory therapies for inflammatory and immune-mediated diseases, has announced the…
LianMedical Completes Merger with LianBio and Launches New Chapter as Medical Device Innovation Company LianMedical, formerly known as LianBio, has announced the successful completion of its previously disclosed corporate merger, marking a significant milestone in the company’s strategic transformation from…
Veradermics Reports Positive Phase 2 Results for Oral VDPHL01 in Female Pattern Hair Loss, Supporting Ongoing Pivotal Development Veradermics, Incorporated, a late-stage biopharmaceutical company focused on developing innovative therapies for pattern hair loss, has announced positive topline results from its…
Incyte Presents Positive Phase 1/2 Data for Latarcibart in Von Willebrand Disease, Supporting Ongoing Phase 3 Development Incyte has announced comprehensive safety and efficacy results from its Phase 1/2 multidose clinical study evaluating VGA039 (latarcibart), an investigational monoclonal antibody designed…
Lineage Cell Therapeutics Advances COR1 Program to Develop Off-the-Shelf Cell Therapy for Corneal Endothelial Disease Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company focused on developing allogeneic, off-the-shelf cell therapies for serious medical conditions, has announced significant progress in the…
HistoSonics Secures CE Mark Approval for Edison® Histotripsy System, Expanding Non-Invasive Liver Tumor Treatment Across Europe HistoSonics has achieved a significant regulatory milestone with the receipt of CE Mark approval for its Edison® Histotripsy System, paving the way for commercialization…
Bausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective Candidate Bausch + Lomb Corporation a leading global eye health company dedicated to helping people see better to live better, today announced topline results from its Phase 2 study evaluating…
Evolus Expands Aesthetic Portfolio with Exclusive U.S. Licensing Agreement for Profhilo®, Europe’s Leading Injectable Skin Quality Treatment Evolus, Inc., a global performance beauty company focused on developing innovative consumer aesthetic brands, has announced an exclusive licensing and distribution agreement with…
U of T, McMaster and Genesys Capital Launch Early-Stage Life Sciences Fund A major new venture capital initiative is set to strengthen Ontario’s life sciences ecosystem by providing early-stage funding to promising health technology startups emerging from academic research. The…
Turn Therapeutics Finalizes Phase 2 Study Design for GX-03 Following Positive Interim Analysis in Atopic Dermatitis Turn Therapeutics, Inc., a clinical-stage biotechnology company focused on developing targeted, non-systemic therapies for inflammatory skin disorders, has announced the completion of a comprehensive…